NTLA Intellia Therapeutics Inc

Price (delayed)

$57.40

Market cap

$3.39B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.29

Enterprise value

$3.23B

Sector: Healthcare
Industry: Biotechnology

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights

The gross profit has soared by 56% YoY and by 23% from the previous quarter
Intellia Therapeutics's revenue has surged by 56% YoY and by 23% QoQ
Intellia Therapeutics's equity has increased by 20% YoY but it has decreased by 6% from the previous quarter
The company's debt rose by 13% YoY but it fell by 4.2% QoQ
The net income has contracted by 33% YoY and by 3.6% from the previous quarter
The EPS has contracted by 16% YoY

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
59.08M
Market cap
$3.39B
Enterprise value
$3.23B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.23
Price to sales (P/S)
54.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
51.88
Earnings
Revenue
$62.34M
EBIT
-$120.32M
EBITDA
-$114.02M
Free cash flow
-$43.5M
Per share
EPS
-$2.29
Free cash flow per share
-$0.74
Book value per share
$5.61
Revenue per share
$1.06
TBVPS
$7.8
Balance sheet
Total assets
$458.56M
Total liabilities
$128.94M
Debt
$22.2M
Equity
$329.62M
Working capital
$360.39M
Liquidity
Debt to equity
0.07
Current ratio
7.45
Quick ratio
7.32
Net debt/EBITDA
1.38
Margins
EBITDA margin
-182.9%
Gross margin
100%
Net margin
-193%
Operating margin
-198.9%
Efficiency
Return on assets
-30.1%
Return on equity
-40.1%
Return on invested capital
-58.6%
Return on capital employed
-29.9%
Return on sales
-193%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
-9.92%
1 week
-13.83%
1 month
-19.61%
1 year
373.6%
YTD
5.51%
QTD
5.51%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$62.34M
Gross profit
$62.34M
Operating income
-$123.96M
Net income
-$120.32M
Gross margin
100%
Net margin
-193%
The gross profit has soared by 56% YoY and by 23% from the previous quarter
Intellia Therapeutics's revenue has surged by 56% YoY and by 23% QoQ
The net income has contracted by 33% YoY and by 3.6% from the previous quarter
The company's operating income fell by 27% YoY and by 2.3% QoQ

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
10.23
P/S
54.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
51.88
The EPS has contracted by 16% YoY
Intellia Therapeutics's equity has increased by 20% YoY but it has decreased by 6% from the previous quarter
The price to sales (P/S) is 102% higher than the 5-year quarterly average of 26.8
Intellia Therapeutics's revenue has surged by 56% YoY and by 23% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
Intellia Therapeutics's ROIC has plunged by 79% YoY and by 9% from the previous quarter
Intellia Therapeutics's ROE has decreased by 22% YoY
The ROA has contracted by 16% YoY but it has grown by 3.5% from the previous quarter
The ROS has grown by 16% from the previous quarter and by 14% YoY

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
Intellia Therapeutics's total liabilities has surged by 82% YoY but it has decreased by 7% QoQ
The total assets has grown by 32% YoY but it has contracted by 7% from the previous quarter
The company's debt is 93% lower than its equity
Intellia Therapeutics's equity has increased by 20% YoY but it has decreased by 6% from the previous quarter
The company's debt rose by 13% YoY but it fell by 4.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.